These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 14621384)

  • 21. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
    Fantoni M; Del Borgo C; Autore C; Barbaro G
    Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What does the term "HIV-associated lipodystrophy" mean?
    Marcason W
    J Am Diet Assoc; 2009 Feb; 109(2):364. PubMed ID: 19167963
    [No Abstract]   [Full Text] [Related]  

  • 23. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
    Vella S; Palmisano L
    J HIV Ther; 2003 May; 8(2):27-8. PubMed ID: 15587479
    [No Abstract]   [Full Text] [Related]  

  • 24. Bullets, balance, or both: medicalisation in HIV treatment.
    Patton C
    Lancet; 2007 Feb; 369(9562):706-7. PubMed ID: 17321320
    [No Abstract]   [Full Text] [Related]  

  • 25. Human immunodeficiency virus disease in the era of HAART: a reevaluation of the mucocutaneous manifestations.
    Johnson RA
    Curr Clin Top Infect Dis; 1999; 19():252-86. PubMed ID: 10472490
    [No Abstract]   [Full Text] [Related]  

  • 26. Prevalence and factors associated with lipodystrophy in AIDS patients.
    Justina LB; Luiz MC; Maurici R; Schuelter-Trevisol F
    Rev Soc Bras Med Trop; 2014; 47(1):30-7. PubMed ID: 24603734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Deviating from classical triple therapy. Nuke sparing concepts as interest focus].
    MMW Fortschr Med; 2011 May; 153(18):38. PubMed ID: 21604594
    [No Abstract]   [Full Text] [Related]  

  • 28. From the Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.
    JAMA; 2001 Jan 24-31; 285(4):402-3. PubMed ID: 11263401
    [No Abstract]   [Full Text] [Related]  

  • 29. HIV treatment series II. Part 3 of 4. Managing side effects.
    Fallon SJ
    Posit Aware; 2003; 14(6):28-32. PubMed ID: 14743791
    [No Abstract]   [Full Text] [Related]  

  • 30. [Lipodystrophy syndrome. Therapeutic progress is still pending].
    Weber K; Heiken H; Stoll M; Schmidt RE; Behrens G
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():28-32. PubMed ID: 15011581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peroxisome proliferator-activated receptor gamma agonists and the treatment of HIV-associated lipoatrophy: unraveling the molecular mechanism of their shortcomings.
    Hadigan C
    J Infect Dis; 2008 Dec; 198(12):1729-31. PubMed ID: 18954262
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment options for lipodystrophy in HIV-positive patients.
    Behrens GM
    Expert Opin Pharmacother; 2008 Jan; 9(1):39-52. PubMed ID: 18076337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV skin complications in the age of HAART: an interview with Toby Maurer.
    Maurer T
    BETA; 1999; 12(4):67-70. PubMed ID: 11367263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What should we know about metabolic syndrome and lipodystrophy in AIDS?
    Signorini DJ; Monteiro MC; Andrade Mde F; Signorini DH; Eyer-Silva Wde A
    Rev Assoc Med Bras (1992); 2012; 58(1):70-5. PubMed ID: 22392319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uses, adverse effects of abuse of corticosteroids. Part II.
    Imam AP; Halpern GM
    Allergol Immunopathol (Madr); 1995; 23(1):2-15. PubMed ID: 7631589
    [No Abstract]   [Full Text] [Related]  

  • 36. Metabolic effects of protease inhibitor therapy.
    Bernasconi E
    AIDS Read; 1999 Jul; 9(4):254-6, 259-60, 266-9. PubMed ID: 12737115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pathophysiology and pathoanatomy of reactions to antimicrobial agents.
    Weinstein L; Weinstein AJ
    Adv Intern Med; 1974; 19():109-34. PubMed ID: 4273657
    [No Abstract]   [Full Text] [Related]  

  • 38. Stavudine in antiretroviral therapy: is this the end?
    Brinkman K
    AIDS; 2009 Aug; 23(13):1727-9. PubMed ID: 19571724
    [No Abstract]   [Full Text] [Related]  

  • 39. [Prevention and therapy of HIV-associated lipodystrophy syndrome and antiretroviral caused metabolic changes].
    Mauss S
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():49-53. PubMed ID: 16385875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of zidovudine in development of lipoatrophy.
    Moyle GJ
    AIDS Read; 2005 Nov; 15(11):591-4, 599-600, 603. PubMed ID: 16329181
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.